Revvity, Inc. (RVTY)
(Delayed Data from NYSE)
$110.69 USD
+2.54 (2.35%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $110.69 0.00 (0.00%) 6:30 PM ET
4-Sell of 5 4
C Value D Growth A Momentum D VGM
Revvity (RVTY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$120.73 | $133.00 | $105.00 | 11.63% |
Price Target
Based on short-term price targets offered by 15 analysts, the average price target for Revvity comes to $120.73. The forecasts range from a low of $105.00 to a high of $133.00. The average price target represents an increase of 11.63% from the last closing price of $108.15.
Analyst Price Targets (15)
Broker Rating
Revvity currently has an average brokerage recommendation (ABR) of 1.94 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 16 brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on 15 recommendations.
Of the 16 recommendations deriving the current ABR, eight are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 50% and 6.25% of all recommendations. A month ago, Strong Buy made up 46.67%, while Buy represented 6.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 7 | 7 | 7 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 7 | 7 | 7 | 7 | 7 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.94 | 1.94 | 2.00 | 2.00 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/16/2024 | Raymond James | Andrew Cooper | Moderate Buy | Moderate Buy |
7/8/2024 | SVB Securities | Puneet Souda | Not Available | Strong Buy |
6/28/2024 | Not Identified | Not Identified | Hold | Hold |
6/3/2024 | Not Identified | Not Identified | Not Available | Hold |
4/1/2024 | Cowen & Co. | Daniel Brennan | Strong Buy | Strong Buy |
2/2/2024 | KeyBanc Capital Markets | Paul Knight | Strong Buy | Strong Buy |
2/2/2024 | Not Identified | Not Identified | Hold | Hold |
2/1/2024 | Robert W. Baird & Co. | Catherine W Schulte | Strong Buy | Strong Buy |
1/16/2024 | UBS | Dan Leonard | Not Available | Hold |
1/4/2024 | Evercore Partners | Vijay Kumar | Hold | Strong Buy |
12/13/2023 | Not Identified | Not Identified | Not Available | Hold |
10/31/2023 | Goldman Sachs | Matthew Sykes | Strong Buy | Strong Buy |
10/31/2023 | Not Identified | Not Identified | Strong Buy | Strong Buy |
9/28/2023 | Not Identified | Not Identified | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.94 |
ABR (Last week) | 1.94 |
# of Recs in ABR | 16 |
Average Target Price | $120.73 |
LT Growth Rate | 8.30% |
Industry | Medical Services |
Industry Rank by ABR | 67 of 252 |
Current Quarter EPS Est: | 1.13 |